Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Charles River (CRL) to $184 from $220 and keeps an Equal Weight rating ...

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Contract researcher Charles River Laboratories, which has been slashing costs as it faces financial headwinds, plans to ...

Charles River is shuttering its pathology facility in Durham, North Carolina, after determining the site “is not a strategic ...

Shares of Charles River Laboratories International Inc. CRL shed 1.91% to $161.62 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX ...

Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

The Convention on International Trade in Endangered Species of Wild Fauna and Flora, or CITES, Standing Committee has voted to defer the ...

The outlook for Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International ...

Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...